Theravance Biopharma (TBPH) Proxy filing summary

Executive summary

• The annual general meeting is scheduled for June 12, 2026, in Dublin, Ireland, with shareholders voting on director elections, auditor ratification, and executive compensation.

• The board reduced its size from nine to six directors to align with strategic priorities and streamline governance.

• Forward-looking statements highlight ongoing strategic reviews, including potential company sale and organizational restructuring following clinical trial outcomes.

Voting matters and shareholder proposals

• Shareholders will vote to elect six directors for one-year terms, ratify Ernst & Young LLP as auditor for 2026, and approve a non-binding advisory resolution on executive compensation.

• The board unanimously recommends voting in favor of all proposals.

• Procedures for shareholder proposals and director nominations for future meetings are detailed, with specific deadlines and requirements.

Board of directors and corporate governance

• The board is composed of six nominees with diverse backgrounds in biopharma, finance, and international business.

• The chair and CEO roles are separated, with an independent director serving as chair.

• Committees include audit, compensation, nominating/corporate governance, development and commercialization, and strategic review, each with defined responsibilities and independent membership.

• Board and committee meetings were well-attended, and director compensation includes cash retainers and equity awards.

• Share ownership and multiple board seat guidelines are enforced for directors.